When details about Dennis Kozlowski's $6,000 shower curtain emerged, which was paid for by his company, investors were outraged. How could you possibly justify a corporation paying for such an exorbitant and unnecessary perk for an executive?
In response to complaints from investors about this and other incidents like it, the SEC passed a rule requiring that companies disclose any perks paid to officers and directors that exceeded $10,000. The rule took effect at the beginning of the year and, according to BusinessWeek, it may be working: "The median value of benefits and perks received by chief executive officers at nearly 100 of the nation's largest companies fell 1.3% in 2006, to $334,433, according to the analysis by Equilar, a Redwood Shores (Calif.) research firm. And the median declined in three of the five perk categories Equilar studied. (There's a one-year lag in compensation disclosures, so this year's proxy filings quantified the perks received in 2006, and last year's proxies detailed those received in 2005.)"
Forced to disclose excessive perks, many companies have decided they would rather avoid the embarrassment. After all, isn't it easier to buy your own shower curtain, rather than give Dan Loeb ammunition to come after you if he ever takes a stake in your company?
The securities laws in the United States are based on disclosure and they appear to be working. If the SEC can force companies to tell shareholders what they're doing, we are increasingly gaining the willingness to stand up and demand change.
Last updated: February 13, 2012: 11:09 AM
Hot Stocks
DailyFinance Headlines
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- Diebold FY11 free cash flow exceeded guidance by more than $10M
- Applied Materials March volatility flat into Q1 and sales outlook
- Rumor: Dendreon active on speculation it canceled a conference presentation
- President Obama to discuss FY2013 budget proposal
- Diebold expects the same quarterly seasonality in FY12 as last years'
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

